"Our study treated over 300 prostate cancer patients across 21 centers throughout the United States. The CyberKnife's unique architecture tracks and automatically corrects for prostate motion, delivering radiation with sub-millimeter accuracy. This exceptional precision allowed us to give a more effective dose of radiotherapy, which translated into superior cancer control. Since we were able to avoid the healthy tissues which lie immediately adjacent to the prostate, side effects were uncommon," said Robert M. Meier, MD, medical director of the Swedish Radiosurgery Center in Seattleand lead investigator of the study published in the International Journal of Radiation Oncology*Biology*Physics.

Added Donald B. Fuller, MD, radiation oncologist at Genesis Healthcare Partners in San Diego and lead investigator of the European Urology Oncology study, "We evaluated an SBRT dosing regimen designed to emulate successful high dose rate (HDR) brachytherapy plans and delivered in four visits. Study outcomes demonstrate that CyberKnife®prostate SBRT is safe and effective for low- and intermediate-risk prostate cancer patients, producing a lower PSA nadir level than previously reported with other external radiotherapy techniques (< 0.1 ng/mL at 4 years and beyond), with minimal impact on quality of life during and after treatment. Of note, our treatment plans required steep dose fall-off from high-dose regions close to the bladder, urethra and rectum that would be difficult to deliver safely without the unique continual image-guidance and automatic correction of the beam aim made possible by the CyberKnife System."


"These multi-center studies reinforce the value the CyberKnife System can bring to a hospital's prostate cancer treatment program and its potential to change the way the disease is treated by many physicians," said Fabienne Hirigoyenberry-Lanson, PhD, Vice President Global Medical and Scientific Affairs, at Accuray. "The system enables clinical teams to achieve their treatment objectives, while providing a cost-effective, non-invasive option that is more convenient for patients. More than 20,000 prostate cancer patients have been treated with the CyberKnife System, clearly demonstrating the importance of these benefits to healthcare professionals and patients alike."


About Accuray
Accuray Incorporated (Nasdaq :ARAY ) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube.

Back to HCB News

Rad Oncology Homepage